New Indication: Adjuvant Ribociclib and Endocrine Therapy in Breast Cancer

  • Study

    A Phase III Multi-center, Randomized, Open-label trial (NATALEE)
    Hormone Receptor-positive, HER2-negative Early Breast Cancer (Stage IIa-III)
    Ribociclib (400 mg/day) + ET (n=2549) vs ET (n=2552


  • Efficacy

    3-year iDFS: 90.4% vs 87.1%, HR:0.74, p=0.0014

  • Safety

    Grade3: Unspcified


    • J Clin Oncol 2023 41:17_suppl, LBA500-LBA500

    Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial

    http://doi.org/10.1200/JCO.2023.41.17_suppl.LBA500

    Reviewed by Elvin Chalabiyev, MD on Jun 24, 2023

    Altai Oncology App
    Download Altai Oncology App On App Store
    Download Altai Oncology App On Play Store
    • Chemotherapy Protocols
    • Summarized References
    • Oncology Drug Specs
    • TNM Staging
    • BSA, CrCl Calculator
    Back to top Drag